Table 6.

Janus Kinase Inhibitors in preclinical and early clinical development

Drug	Specificity	Clinical Status	Diseases
OP0155 [199]	JAK3	Preclinical	Rat adjuvant induced arthritis
VR588 [200]	Pan JAK inhibitor (inhalational)	Preclinical	Asthma
SHR0302 [201]	JAK1, JAK2, JAK3 (strongest binding to JAK1)	Phase 1	Rheumatoid arthritis
Pf-04965842 [202]	JAK1	Phase 2b (ClinicalTrials.gov. NCT02780167)	Moderate To Severe Atopic Dermatitis
JTE-052 [203]	JAK1, 2, 3 and Tyk2	Phase 2 (in Japan)	Atopic dermatitis, auoimmune disorders

JAK Janus kinase